DOCSLIB.ORG

Regulation on the Amendments of Regulation No. 233.2001.Pdf Date

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulation on the Amendments of Regulation No. 233.2001.Pdf Date REGULATION on the (12th) amendment of Regulation No. 233/2001, on habit-forming and narcotic substances and other controlled substances. Article 1 The title “The Minister of Health and Social Security” in the second paragraph of Article 2, the first paragraph of Article 6, in two places in the first paragraph of Article 7 and in Article 8 of the Regulation shall be replaced (with the appropriate grammatical case inflexions in Icelandic) by: The Icelandic Medicines Agency. Article 2 The words “the Minister” in two places in the second paragraph of Article two and in the third paragraph of Article 7 of the Regulation shall be replaced (with the appropriate grammatical cases inflections in Icelandic): the Icelandic Medicines Agency. Article 3 The words “on the prescribing of drugs and the design of prescriptions and the Regulation on the processing of prescriptions, the recording and dispensing of medicinal products” in the third paragraph of Article 3 shall be replaced by: medicinal product prescriptions and the dispensing of medicinal products, with subsequent amendments. Article 4 The word “prescribed” in the first paragraph of Article 4, the title of Chapter IV, in three places in the first, second and fourth paragraphs of Article 10 and in two places in the first and second paragraphs of Article 11 of the Regulation shall be replaced (with the appropriate grammatical case inflexions in Icelandic) by: dispensed. Article 5 The following amendments shall be made to the fifth paragraph of Article 5 of the Regulation: a. The title “the Ministry of Health and Social Security” shall be replaced by: the Icelandic Medicines Agency. b. The word “Ministry” shall be replaced by: the Icelandic Medicines Agency. Article 6 The title “the Ministry of Health and Social Security” in the second paragraph of Article 6, the second paragraph of Article 7, Article 8 and the first paragraph of Article 9 of the Regulation shall be replaced (with the appropriate grammatical case inflexions in Icelandic) by: the Icelandic Medicines Agency. Article 7 The words “to the Ministry” in the first paragraph of Article 9 of the Regulation shall be replaced by: to the Icelandic Medicines Agency. Article 8 The word “Drugs” [Lyfjum in Icelandic, i.e. the dative case] in the first paragraph of Article 10 of the Regulation shall be replaced by: Drugs [Lyf in Icelandic, i.e. the accusative case; this amendment does not affect the English translation]. Article 9 The words “are prescribed” in the third paragraph of Article 10 of the Regulation shall be replaced by: be dispensed. Article 10 The word “prescribed” in Article 12 of the Regulation shall be replaced by: dispensed. Article 11 The following amendments shall be made to the following substances in Appendix I: Substance Other name IUPAC (International Internatio B Exemptio Union of Pure and nal Agree- ns and Applied Chemistry) ments Comment s 1,4-butanediol BD butane-1,4-diol x 5) 4-fluoroamphetamine 4-FA 1 - (4 - fluorophenyl)propan - P II Para- 2-amine fluoroamphetamine PFA 4'-Fluoro-α- 4-fluoro-α-PVP, 1-(4-fluorophenyl)-2-(1- x pyrrolidinopentiophenone 4F-alfa-PVP pyrrolidinyl)-1-pentanone 4-methylethcathinone 4-MEC 2-ethylamino-1-(4- P II methylphenyl)propan-1- one 5F-AKB-48 5F-APINACA N-(1-adamantyl)-1-(5- PII fluoropentyl)-1H-indazol- 3- carboxamid 5F-MDMB-PINACA 5F-ADB N-(1-methoxycarbonyl- P II 2,2-dimethylpropyl)-1-(5- fluoropentyl)-1H-indazol- 3-carboxamid AB-PINACA N-[(2S)-1-amino-3- PII methyl-1-oxobutan-2-yl]- 1-pentylindazole-3- carboxamide Carfentanil Carfentanyl Methyl 4-[(1- N IV oxopropyl)phenylamino]- 1-(2-phenylethyl)-4- piperidinecarboxylate Ethylphenidate ethyl 2-phenyl-2- P II piperidin-2-ylacetate MDMB-CHMICA (methyl-2-(1- PII (cyclohexylmethyl)-1H- indol-3-carboxamido)- 3,3-dimethylbutanoat) Pentedrone 1-phenyl-2- P II (methylamino)pentan-1- one Article 12 The words “the first paragraph of Article 7 of the Medicinal Products Act, No. 93/1994, with subsequent amendments” and “the seventh paragraph of Article 7 of the same Act” in item 4 in the section “Exemptions and comments” in Appendix I shall be replaced, in two places, by: the Medicinal Products Act. Article 13 A new item shall be added to the section “Exemptions and comments” in Appendix I, reading as follows: 5) The following are also exempted from the requirement regarding import/export licences: a) Products that may be marketed in Iceland under other legislation and contain the substance in trace quantities only. b) The substance itself, if the purpose for which it is intended constitutes industrial production and the final product produced does not have, or is not considered to have, psychotropic effects and the raw material cannot be recovered from the final product, or if it is believed that it cannot be recovered from the final product. Article 14 The following substances shall be added to the list in Appendix I: IUPAC (International Union of Pure and International Exemptions/ Substance Other name Applied Chemistry) and other technical B Agreements Comments names N,N-diethyl-6-methyl-1-propanoyl-9,10- 1P-LSD 1-propionyllysergid x didehydroergoline-8-carboxamide 2-(ethylamino)-1-(3- 2-(ethylamino)-1-(3-chlorophenyl)propan-1- x chlorophenyl)propan-1-one one 2-(ethylamino)propiophenone 2-(ethylamino)-1-phenylpropan-1-one x 2,3-DMMC 2,3-dimethylmethcathinone x 2,4-DMMC 2,4-dimethylmethcathinone x 1-(2,4-dimethylphenyl)-2-pyrrolidine-1-yl- 2,4-DMPPP x propan-1-one 2,5-dimethoxy-4- 1-(4-fluoro-2,5-dimethoxyphenyl)propan-2- x fluoroamphetamine amine 2,5-dimethoxy-4- 1-(2,5-dimethoxy-4-nitrophenyl)propan-2- x nitroamphetamine amine 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2- 25B-NBF x fluorobenzyl)ethanamine 2-([2-(4-bromo-2,5- 25B-NBOH x dimethoxyphenyl)ethylamino]methyl)phenol 2-(4-chloro-2,5-dimethoxiphenyl)-N-(2- 25C-NBF x fluorobenzyl)ethanamine IUPAC (International Union of Pure and International Exemptions/ Substance Other name Applied Chemistry) and other technical B Agreements Comments names 2-[([2-(4-ethyl-2,5- 25E-NBOH x dimethoxiphenyl)ethyl]amino)methyl]phenol 2-(4-ethyl-2,5-dimethoxiphenyl)-N-(2- 25E-NBOMe x methoxybenzyl)ethanamine 2-(2,5-dimethoxy-3,4-dimethylphenyl)-N-(2- 25G-NBOMe x methoxybenzyl)ethanamine 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(3,4- 25I-NB34MD x methylenedioxyphenyl)methyl]ethanamine 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2- 25I-NBF x fluorobenzyl)ethanamine 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2,3- 25I-NBMD x methylenedioxyphenyl)methyl]ethanamine 2-([2-(4-iodo-2,5- 25I-NBOH x dimethoxyphenyl)ethylamino]methyl)phenol 2-(2,5-dimethoxy-4-nitrophenyl)-N-(2- 25N-NBOMe x methoxybenzyl)ethanamine 2-(8-bromo-2,3,6,7-tetrahydrofuro[2,3- 2C-B-FLY x f][1]benzofuran-4-yl)ethanamine 2C-F* 2,5-dimethoxy-4-fluorophenethylamine x 2C-H 2,5-dimethoxyphenethylamine x 2-chloro-4,5- 2-Cl-4,5-MDMA x methylenedioxymethamphetamine 1-(2-chlorophenyl)-2-(methylamino)-1- 2-CMC 2-Chloromethcathinone x propanone 2-MEC 2-methyl-N-ethylcathinone x N-[1-(2-phenylethyl)piperidin-4-yl]-N-(2- 2-methylacetylfentanyl x methylphenyl)acetamide IUPAC (International Union of Pure and International Exemptions/ Substance Other name Applied Chemistry) and other technical B Agreements Comments names 2-methylamphetamine 2-MA 1-(2-methylphenyl)propan-2-amine x 2-(methylamino)hexanophenone 2-methylamino-1-phenylhexan-1-one x 1-[4-(3-phenylprop-2-en-1-yl)-2- 2-methyl-AP-237 x methylpiperazin-1-yl]butan-1-one 3,4-DCEC 3,4-dichloroethcathinone x 3,4-Dichloro-N,N- 2-(cyclohexyl(methyl)amino)-1-(3,4- x cyclohexylmethylmethcathinone dichlorophenyl)propan-1-one methyl-2-(3,4-dichlorophenyl)-2-(piperidin- 3,4-dichloromethylphenidate x 2-yl)acetate 1-(3,4-dimethoxyphenyl)-2-pyrrolidin-1- 3,4-Dimethoxy-α-PHP x ylhexan-1-one 3,4-DMA 3,4-dimethoxyamphetamine x N-[2-(dimethylamino)cyclohexyl]-N- 3,4-methylenedioxy-U-47700 x methyl-2H-1,3-benzodioxol-5-carboxamide 1-(3-bromophenyl)-2-(methylamino)propan- 3-bromomethcathinone 3-BMC x 1-one 3-Desoxy-MDPV 5-DMFPV 5-dihydrobenzofuranpyrovalerone x N-(3-fluorophenyl)-N-[1-(2- 3-Fluorofentanyl x phenylethyl)piperidin-4-yl]propanamide 3-fluoroethylamphetamine 3-FEA N-ethyl-1-(3-fluorophenyl)propan-2-amine x 3-fluorophenmetrazine 3-FPM 2-(3-fluorophenyl)-3-methylmorpholine x 7-bromo-3-hydroxy-5-(2-chlorophenyl)-1,3- 3-hydroxyphenazepam x dihydro-2H-1,4-benzodiazepin-2-one IUPAC (International Union of Pure and International Exemptions/ Substance Other name Applied Chemistry) and other technical B Agreements Comments names 3-hydroxyphencyclidine 3-HO-PCP 3-[1-(piperidin-1-yl)cyclohexyl]phenol x 2-(ethylamino)-1-(3-chlorophenyl)propan-1- 3-chloroethcathinone, 3-CEC x one N-ethyl-1-(3-methoxyphenyl)cyclohexan-1- 3-methoxyeticyclidine 3-MeO-PCE x amine 3-methyl-N-(1-phenethylpiperidin-4-yl)-N- 3-methylcrotonylfentanyl x phenylbut-2-enamide 1-(3-fluorophenyl)-2-(methylamino)propan- 3-methylflephedrone x 1-one N-phenyl-N-[1-(2-phenylethyl)piperidin-4- 3-phenylpropanoylfentanyl x yl]-3-phenylpropanamide 2-amino-4-methyl-5-(4-methylphenyl)-2- 4,4’-dimethylaminorex 4,4'-DMAR P II oxazoline 4-AcO-DMT 4-acetoxy-N,N-dimethyltryptamine x 4-AcO-MET 4-acetoxy-N-methyl-N-ethyltryptamine x 4-anilinopiperidine 4-AP N-phenyl-4-piperidinamine x 4-BMC 4-bromomethcathinone x 4Br-α-PPP 4-bromo-α-pyrrolidinopropiophenone x 4Br-α-PVP 4-bromo-α-pyrrolidinovalerophenone x 4-CA 4-chloroamphetamine x IUPAC (International Union of Pure and International Exemptions/ Substance Other name Applied Chemistry) and other technical B Agreements Comments names 4-CBC 4-chloro-N-butylcathinone x 4-CEC 4-chloroethcathinone x 4-CIC 4-chloroisopropylcathinone x 4-CMA
Load more

Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
    [Show full text]
  • How Pre-Clinical Studies Have Influenced Novel Psychoactive Substance Legislation in the UK and Europe
    Article How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe Santos, Raquel, Guirguis, Amira and Davidson, Colin Available at http://clok.uclan.ac.uk/31793/ Santos, Raquel ORCID: 0000-0003-3129-6732, Guirguis, Amira and Davidson, Colin ORCID: 0000-0002-8180-7943 (2020) How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe. British Journal Of Clinical Pharmacology, 86 (3). pp. 452-481. ISSN 0306-5251 It is advisable to refer to the publisher’s version if you intend to cite from the work. http://dx.doi.org/10.1111/bcp.14224 For more information about UCLan’s research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>. For information about Research generally at UCLan please go to http://www.uclan.ac.uk/research/ All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the policies page. CLoK Central Lancashire online Knowledge www.clok.uclan.ac.uk How Pre-Clinical Studies Have Influenced Novel Psychoactive Substance Legislation in The UK and Europe Raquel Santos1, Amira Guirguis2 & Colin Davidson1* 1School of Pharmacy & Biomedical Sciences, Faculty of Clinical & Biomedical Sciences, University of Central Lancashire, UK. 2Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, Wales, UK. *Corresponding author Colin Davidson School of Pharmacy and Biomedical Science Faculty of Clinical & Biomedical Sciences University of Central Lancashire Preston PR1 2HE +44 (0)1772 89 3920 [email protected] Key words: novel psychoactive substance, legal high, legislation, toxicity, abuse Running Head: review of NPS pharmacology The authors have no conflicts of interest to declare Page | 1 Abstract Novel psychoactive substances (NPS) are new drugs of abuse.
    [Show full text]
  • Free PDF Download
    European Review for Medical and Pharmacological Sciences 2019; 23: 3-15 Use of cognitive enhancers: methylphenidate and analogs J. CARLIER1, R. GIORGETTI2, M.R. VARÌ3, F. PIRANI2, G. RICCI4, F.P. BUSARDÒ2 1Unit of Forensic Toxicology, Sapienza University of Rome, Rome, Italy 2Section of Legal Medicine, Universita Politecnica delle Marche, Ancona, Italy 3National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy 4School of Law, University of Camerino, Camerino, Italy Abstract. – OBJECTIVE: In the last decades, phenidate analogs should be undertaken to re- several cognitive-enhancing drugs have been duce the uprising threat, and education efforts sold onto the drug market. Methylphenidate and should be made among high-risk populations. analogs represent a sub-class of these new psy- choactive substances (NPS). We aimed to re- Key Words: view the use and misuse of methylphenidate and Cognitive enhancers, Methylphenidate, Ritalin, Eth- analogs, and the risk associated. Moreover, we ylphenidate, Methylphenidate analogs, New psycho- exhaustively reviewed the scientific data on the active substances. most recent methylphenidate analogs (methyl- phenidate and ethylphenidate excluded). MATERIALS AND METHODS: Literature Introduction search was performed on methylphenidate and analogs, using specialized search engines ac- cessing scientific databases. Additional reports Consumption of various pharmaceutical drugs were retrieved from international agencies, in- by healthy individuals in an attempt to improve stitutional websites, and drug user forums. cognitive faculties is on the rise, whether for aca- RESULTS: Methylphenidate/Ritalin has been demic or recreational purposes1. These substances used for decades to treat attention deficit disor- are stimulants that preferentially target the cate- ders and narcolepsy. More recently, it has been used as a cognitive enhancer and a recreation- cholamines of the prefrontal cortex of the brain to al drug.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Peakal: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra
    PeakAL: Protons I Have Known and Loved — Fifty shades of grey-market spectra Stephen J. Chapman* and Arabo A. Avanes * Correspondence to: Isomer Design, 4103-210 Victoria St, Toronto, ON, M5B 2R3, Canada. E-mail: [email protected] 1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors across North America and Europe were acquired and compared. Members from each of the principal phenylethanamine families were analyzed: eleven para- substituted 2,5-dimethoxyphenylethanamines (the 2C and 2C-T series); four para-substituted 3,5-dimethoxyphenylethanamines (mescaline analogues); two β-substituted phenylethanamines; and ten N-substituted phenylethanamines with a 2-methoxybenzyl (NBOMe), 2-hydroxybenzyl (NBOH), or 2,3-methylenedioxybenzyl (NBMD) amine moiety. 1H NMR spectra for some of these compounds have not been previously reported to our knowledge. Others have reported on the composition of “mystery pills,” single-dose formulations obtained from retail shops and websites. We believe this is the first published survey of bulk “research chemicals” marketed and sold as such. Only one analyte was unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.[1] Keywords: 1H NMR, drug checking, grey markets, research chemicals, phenylethanamines, N-benzyl phenylethanamines, PiHKAL DOI: http://dx.doi.org/10.16889/isomerdesign-1 Published: 1 August 2015 Version: 1.03 “Once you get a serious spectrum collection, Nevertheless, an inherent weakness of grey markets is the the tendency is to push it as far as you can.”1 absence of regulatory oversight.
    [Show full text]
  • Swedish Code of Statutes
    1. ------IND- 2018 0506 S-- EN- ------ 20190508 --- --- FINAL Swedish Code of Statutes Ordinance amending the Ordinance (1999:58) banning certain products SFS 2018:1587 that are harmful to health Published Issued on 4 October 2018 on 9 October 2018 The Government hereby lays down1 that the annex to the Ordinance (1999:58) prohibiting certain products that are harmful to health shall read as set out below. ___________ This ordinance shall enter into force on 12 November 2018. On behalf of the government ANNIKA STRANDHÄLL Kjell Rempler (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Annex SFS 2018:1587 List of products to be regarded as products that are harmful to health in accordance with the Ordinance prohibiting certain products that are harmful to health N-methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine (MBDB) 1-(3,4-methylenedioxyphenyl)-2-butylamine (BDB) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT) 5-methoxy-alphamethyltryptamine (5-MeO-AMT) 2,5-dimethoxy-4-ethylphenethylamine (2C-E) alpha-methyltryptamine (AMT) 2,5-dimethoxy-4-chlorophenethylamine (2C-C) 2,5-dimethoxy-4-methylphenethylamine (2C-D) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT) gamma-butyrolactone (GBL) 1,4-butanediol (1,4-BD) 4-acetoxy-N,N-methylisopropyltryptamine
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 6,967,201 B1 Briner Et Al
    US006967201B1 (12) United States Patent (10) Patent N0.: US 6,967,201 B1 Briner et al. (45) Date of Patent: *Nov. 22, 2005 (54) BENZOFURYLPIPERAZINES AND (56) References Cited BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS U.S. PATENT DOCUMENTS 5,698,766 A 12/1997 Julius et 211. (75) Inventors: Karin Briner, Indianapolis, IN (US); 6,638,936 B1 * 10/2003 Briner et a1. Joseph Paul Burkhart, Plain?eld, IN (US); Timothy Paul Burkholder, FOREIGN PATENT DOCUMENTS Carmel, IN (US); Brian Eugene EP 0 006 524 A 1/1980 Cunningham, Martinsville, IN (US); EP 0 189 612 A 8/1986 Matthew Joseph Fisher, Mooresville, W0 W0 95 11243 A 4/1995 IN (US); William Harlan Gritton, W0 W0 97 08167 A 3/1997 Zionsville, IN (US); Shawn W0 W0 97 36893 A 10/1997 Christopher Miller, Noblesville, IN (US); J e?'rey Thomas Mullaney, OTHER PUBLICATIONS Indianapolis, IN (US); Matthew Robert Kuipers W. et al: “N4-unsubstituted 1-6 nl-arylpiperaZines Reinhard, Indianapolis, IN (US); as high-affinity 5 -HT1A recept r ligands” Journal of Medici Dennis Charles Thompson, nal Chemistry., vol. 38, No. 11, May 26, 1995, pp. 1942 Indianapolis, IN (US); Leonard Larry 1954, XP002153536 American Chemical Society. Washing Winneroski, Greenwood, IN (US); ton., US ISSN: 0022-2623. Yanping Xu, Fishers, IN (US) * cited by examiner (73) Assignee: Eli Lilly and Company, Indianapolis, Primary Examiner—Emily Bernhardt IN (US) (74) Attorney, Agent, or Firm—R. Craig Tucker (57) ABSTRACT (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Understanding and Challenging the Drugs: Chemistry and Toxicology
    UNDERSTANDING AND CHALLENGING THE DRUGS: CHEMISTRY AND TOXICOLOGY Presenter: • Dr. Jasmine Drake, Graduate Program Director and Assistant Professor, Administration of Justice Department, Barbara Jordan-Mickey Leland School of Public Affairs, Texas Southern University NACDL Training Defending Drug Overdose Homicides in Pennsylvania Penn State Harrisburg, Middletown, PA November 6th, 2019 11:30- 12:45 p.m. Understanding & Challenging the Drugs: Chemistry & Toxicology Dr. Jasmine Drake, Forensic Science Learning Laboratory, Texas Southern University I. Opioid Drug Classifications A. Types of Opioids B. Classic vs. Synthetic C. Toxicology of Opioids 1) How opioids interact with the body 2) Addiction (psychological vs. physiological II. New Classes of Drugs A. Emerging Threats B. Potency III. National Trends in Opioid Overdose Deaths in the U.S. A. Based on State B. Ethnicity C. Drug-Type (prescription vs. fentanyl vs. heroin) IV. Trends of Opioid Overdose Deaths in Philadelphia A. Based on Ethnicity B. Drug Type (prescription vs. fentanyl vs. heroin) V. Legal Considerations to the Opioid Epidemic A. Punitive Measures vs. Rehabilitative Treatment B. Progressive Jurisdictions Nationwide C. New Legal Measures in Philadelphia VI. Toxicology Reports A. What’s in the report? B. Key Aspects of the Tox Report C. Terminology D. Evaluating and Interpreting the data? E. Questions and considerations. VII. Conclusion and Discussion A. Case Specific Examples B. Sample Toxicology Reports The Opioid Epidemic: What labs have to do with it? Ewa King, Ph.D. Associate Director of Health RIDOH State Health Laboratories Analysis. Answers. Action. www.aphl.org Overview • Overdose trends • Opioids and their effects • Analytical testing approaches • Toxicology laboratories Analysis. Answers. Action.
    [Show full text]
  • Advisory Council on the Misuse of Drugs
    ACMD Advisory Council on the Misuse of Drugs Chair: Dr Owen Bowden-Jones Secretary: Zahi Sulaiman 1st Floor (NE), Peel Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 1121 [email protected] Sarah Newton MP Minister for Vulnerability, Safeguarding and Countering Extremism Home Office 2 Marsham Street London SW1P 4DF 10 March 2017 Dear Minister, RE: Further advice on methylphenidate-related NPS In February 2016, my predecessor Professor Les Iversen wrote to the then minister for Preventing Abuse, Exploitation and Crime, requesting that the Temporary Class Drug Order (TCDO) on seven methylphenidate-related Novel Psychoactive Substances be re-laid for a further 12 months. This TCDO was re-laid until June 2017, to allow the Advisory Council on the Misuse of Drugs (ACMD) more time to collect the evidence required to provide further advice for full control under the Misuse of Drugs Act 1971. The ACMD believes that the TCDO has been effective in reducing the prevalence of these substances and that the TCDO level of control was proportionate in the interim. I am now pleased to present to you the ACMD’s further advice on this matter in the enclosed report. The ACMD’s recommendation for full control applies to the seven substances currently controlled under the TCDO and extends to an additional five closely-related substances. These five similar substances have subsequently appeared on markets following the TCDO and are included in this advice due to their potential for similar harms. Recommendation The ACMD recommends that the
    [Show full text]
  • UNODC, Synthetic Drugs in East and Southeast Asia
    Synthetic Drugs in East and Southeast Asia Latest developments and challenges May 2020 Global SMART Programme Copyright © 2020, United Nations Office on Drugs and Crime (UNODC). This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. UNODC would appreciate receiving a copy of any publication that uses this publication as a source. Acknowledgements This report was prepared by the Global Synthetic Monitoring: Analyses, Reporting and Trends (SMART) Programme, Laboratory and Scientific Section with the support of the UNODC Regional Office for Southeast Asia and the Pacific. Supervision, direction and review Justice Tettey, Chief, Laboratory and Scientific Section Jeremy Douglas, Regional Representative, Southeast Asia and the Pacific Research and drafting Martin Raithelhuber, Illicit Synthetic Drugs Expert Tun Nay Soe, Inter-regional Programme Coordinator Inshik Sim, Drug Programme Analyst, Southeast Asia and the Pacific Joey Yang Yi Tan, Junior Professional Officer in Drug Research Graphic design and layout Akara Umapornsakula, Graphic Designer Administrative support Jatupat Buasipreeda, Programme Assistant The present report also benefited from the expertise and valuable contributions of UNODC colleagues in the Laboratory and Scientific Section and the Regional Office for Southeast Asia and the Pacific, including Tsegahiwot Abebe Belachew, Rebecca Miller, Reiner Pungs, and John Wojcik. Disclaimer This report has not been formally edited. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of UNODC or the Secretariat of the United Nations concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • UCSF UC San Francisco Previously Published Works
    UCSF UC San Francisco Previously Published Works Title Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review Permalink https://escholarship.org/uc/item/8xh0s7nf Authors Armenian, Patil Vo, Kathy Barr-Walker, Jill et al. Publication Date 2017-10-01 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review Patil Armenian, Kathy Vo, Jill Barr-Walker, Kara Lynch University of California, San Francisco-Fresno and University of California, San Francisco Keywords: opioid, synthetic opioids, fentanyl, fentanyl analog, carfentanil, naloxone Abbreviations: 4-ANPP: 4-anilino-N-phenethyl-4-piperidine; ANPP 4Cl-iBF: 4-chloroisobutyryfentanyl 4F-iBF: 4-fluoroisobutyrfentanyl AEI: Advanced electronic information AMF: alpha-methylfentanyl CBP: US Customs and Border Protection CDC: Centers for Disease Control CDSA: Controlled Drug and Substance Act (Canada) CNS: central nervous system DEA: US Drug Enforcement Agency DTO: Drug trafficking organization ED: Emergency department ELISA: enzyme-linked immunosorbent assay EMCDDA: European Monitoring Centre for Drug and Drug Addiction FDA: US Food and Drug Administration GC-MS: gas chromatography mass spectrometry ICU: intensive care unit IN: intranasal IV: intravenous LC-HRMS: liquid chromatography high resolution mass spectrometry LC-MS/MS: liquid chromatography tandem mass spectrometry MDA: United Kingdom Misuse of Drugs Act NPF: non-pharmaceutical fentanyl THF-F: tetrahydrofuranfentanyl US: United States USPS: US Postal Service UNODC: United Nations office on drugs and crime 1. Introduction The death rate due to opioid analgesics nearly quadrupled in the US from 1999 to 2011 and was responsible for 33,091 deaths in 2015 (CDC, 2014; Rudd et al., 2016).
    [Show full text]